LINC-PINT alleviates lung cancer progression via sponging miR-543 and inducing PTEN

Shu Wang1, Wenyang Jiang2, Xinghua Zhang2

  • 1Department of Gerontology, The First Affiliated Hospital of Nanchang University, Nanchang, China.

Cancer Medicine
|January 26, 2020
PubMed

Insights

Long intergenic nonprotein coding RNA p53-induced transcript (LINC-PINT) is decreased in non-small cell lung cancer (NSCLC). Upregulating LINC-PINT inhibits NSCLC cell proliferation, migration, and invasion by targeting miR-543 and PTEN.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Long intergenic nonprotein coding RNA p53-induced transcript (LINC-PINT) is implicated in various cancers.
  • The role of LINC-PINT in non-small cell lung cancer (NSCLC) progression requires further investigation.

Purpose of the Study:

  • To investigate the functional role of LINC-PINT in NSCLC progression.
  • To elucidate the molecular mechanism underlying LINC-PINT's action in lung cancer.

Main Methods:

  • Quantitative analysis of LINC-PINT expression in NSCLC tissues and cell lines.
  • In vitro experiments involving LINC-PINT upregulation in A549 and H1299 cells (proliferation, colony formation, apoptosis, cell cycle, migration, invasion assays).
  • In vivo xenograft models and molecular mechanism studies (miRNA target prediction and validation, Western blotting for protein expression).

Main Results:

  • LINC-PINT expression was significantly decreased in NSCLC.
  • Overexpression of LINC-PINT suppressed NSCLC cell proliferation, colony formation, migration, and invasion.
  • LINC-PINT upregulation induced apoptosis and G1 phase cell cycle arrest.
  • LINC-PINT negatively regulated miR-543, and miR-543 targeted PTEN, inhibiting its expression.
  • LINC-PINT overexpression reversed the inhibitory effect of miR-543 on PTEN.

Conclusions:

  • LINC-PINT plays a critical role in suppressing NSCLC progression.
  • LINC-PINT acts as a tumor suppressor in NSCLC by sponging miR-543 and upregulating PTEN.
  • LINC-PINT represents a potential therapeutic target for NSCLC treatment.